3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Lung Neoplasms
3
Thyroid Neoplasms
2
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Medullary
2
Carcinoma, Bronchogenic
2
Carcinoma
2
Adenocarcinoma
2
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Glandular and Epithelial
1
Multiple Endocrine Neoplasia Type 2a
1
Locally Advanced Thyroid Gland Carcinoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Interventions
lutetium Lu 177 dotatate
34
Everolimus
33
lanreotide
13
gallium Ga 68 dotatate
13
Temozolomide
13
Magnetic Resonance Spectroscopy
13
Nivolumab
12
pembrolizumab
11
Octreotide
11
Capecitabine
11
177Lu-octreotide, DOTA(0)-Tyr(3)-
10
cabozantinib
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
surufatinib
8
Sunitinib
8
Specimen Handling
7
Carboplatin
7
pasireotide
6
amino-acid, glucose, and electrolyte solution
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
Lutetium-177
5
Ipilimumab
5
Fluorodeoxyglucose F18
5
Etoposide
5
Cisplatin
5
Bevacizumab
5
telotristat ethyl
4
olaparib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neuroendocrine Tumors
×
pralsetinib
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA